Guys. load up on GIG....it's the real deal. 300% potential 1 year upside guaranteed
No, it's not. I think you might be referring to the link for the earnings release. What the poster provided was the link for the conference call....those are two different things.
GIG beat net income consensus estimates by 3c/share and reported in-line numbers from June 29 raised guidance. Fastest growing company in semiconductor industry ( 20%/year CAGR).
Highlights/Excerpts from conference call (for full CC go to seekingalpha GIG):
In the second quarter, we delivered our first quarter of GAAP profitability free of nonrecurring items, record non-GAAP profitability and adjusted EBITDA, and generated more than $1 million cash from operations.
To briefly summarize the second quarter results, revenue was up the fifth straight quarter to $9.8 million, which represents an increase of 9% sequentially and 22% over the second quarter of 2014. GAAP and non-GAAP gross margin continued to improve significantly, up to 63% and 66% respectively, 3% and 4% from the previous quarter of 60% and 62% respectively.
GAAP net income free of nonrecurring items was a record $500,000 or net income of $0.02 per diluted share. Non-GAAP net income was a record level of $2.1 million or net income of $0.06 per diluted share, 50% higher than the entire 2014 year’s net income of $0.04 per diluted share. Adjusted EBITDA was a new record of $2.8 million.
And finally, cash increased by about $700,000 compared to the previous quarter, ending with a balance of $18.4 million (or 61c/share & zero debt).
With our current positive outlook for the business, we expect Q3 to show revenue increases to about $10.3 million, which will mark the highest revenue record quarter ever in the history of GigOptix.
I want to reiterate our previous updated guidance for 2015 revenue to be at least $39 million for the entire year, which would make this year the record revenue year for GigOptix and also to be the year with the best profitability and cash generation ever.
My take - GIG will be trading North of $2.5 soon following expected analyst's upgrades....:)
GigOpttix has 60c/share cash and zero debt....Analysts have a $3/share target which will likely be raised after today's earnings report.
Preannouncement: (June 29, 2015)
- Record quarterly revenues
- Record non-GAAP profitability
- First GAAP-profitable quarter ever
- Raised guidance for FY 2015 - This means that 3Q & 4Q 2015 will also be GAAP profitable
- Growing at over 20%/year CAGR
- fastest growing company in the semi industry
Other excerpts from preannouncement:
Continued robust demand in the firm's High Speed Communications product line - primarily for its QSFP+ drivers and trans-impedance amplifiers (TIAs) for data-center active optical cables (AOC) and transceivers, and the linear-coherent 100Gbps and 200Gbps drivers for use in long-haul and metro telecom applications, as well as new business opportunities in the Industrial product line – has resulted in the higher than initially forecasted revenue.
Based on these preliminary revenue results for second-quarter 2015, along with continued healthy margin performance and tight expense controls, GigOptix also believes that it will achieve positive GAAP net income and record non-GAAP profitability.
In addition, as a result of the better than initially forecasted revenue performance for first-half 2015 (up 22% year-on-year) and the current continuous strong growth outlook for both the third quarter and the remainder of 2015, GigOptix has raised its revenue forecast for full-year 2015 by 4% (from the previously announced guidance midpoint of $37.5m) to at least $39m (up 19% on $32.9m for 2014).
I' ll put it my alerts. Thank you
GIG recently raised guidance for 2Q 2015 and FY 2015. The company will start reporting GAAP profitability going forward on over 20% CAGR yearly growth rate and over 60% gross margins. The company is also bidding to acquire larger company GSIT. The combined company would generate over $100 million in revenues and be highly GAAP profitable........you must do your DD now because this is a high-reward low-risk opportunity .....
GIG even without cash-rich GSIT has over 60c/share cash with no debt....the market is only valuing the stock at $1/share over cash!!!
Analysts covering the stock has a $3/share target which will likely be upgraded after tomorrow's earnings release
Seeking alpha has a nice article on GIG to help you begin your DD but I can't post the link here. Search for Seekingalpha GIG and you'll find it .....also go to GIG's news about the preannouncement that lifted the stock 30c to $1.95 when that's happened a few weeks ago. GIG is still under the radar but it will not anymore after the July 27 AH earnings release.
MMs have been manipulating the stock in an effort to accumulate shares.....Your best opportunity to get in on a ground level is Monday morning......The price will rally as earnings AH approach....after that it's blue skies baby!!!!
I agree. Just a ploy of MMs on a (currently) under the radar gem. GIG ill not be under the radar anymore after Monday's record earnings and strong outlook.
I'll load up the boat tomorrow. I see that institutions have been loading up lately. Thanks!
GigOptix Increases Second Quarter and Fiscal 2015 Revenue Guidance
Preliminary Q2FY15 revenue of approximately $9.8 million, 8 percent above Q1FY15 and 5% above the previously provided guidance midpoint of $9.4 million
Revenue guidance for fiscal year 2015 increased to at least $39 million, up approximately 19% from fiscal 2014, and 4 percent from the previously provided guidance midpoint of $37.5 million
Expect to achieve positive GAAP net income and record non-GAAP profitability in Q2FY15
Business Wire GigOptix, Inc.
SAN JOSE, Calif.--(BUSINESS WIRE)--
GigOptix, Inc. (NYSE MKT:GIG) a leading supplier of advanced high-speed semiconductor components for use in long-haul, metro, cloud connectivity, data centers, consumer electronics links and interactive applications, through optical and wireless communications networks, today announced it currently expects revenue for the second quarter of fiscal year 2015, ended June 28, 2015, will be approximately $9.8 million, or an increase of approximately 8% from the first quarter of fiscal year 2015, and approximately 5% above the quarter’s guidance midpoint of $9.4 million provided on April 27, 2015 (revenue up 22% above 1Q 2014).
Based on these preliminary revenue results in the second quarter of fiscal year 2015, along with continued healthy margin performance and tight expense controls, GigOptix also believes it will achieve positive GAAP net income and record non-GAAP profitability.
In addition, as a result of the better than initially forecasted revenue performance for the first half of fiscal 2015, which grew 22% over the first half of fiscal 2014, and the current continuous strong growth outlook for the third quarter and the remainder of fiscal year 2015, GigOptix today increased its revenue forecast for fiscal 2015 to at least $39 million, up approximately 4% from the previously announced guidance midpoint of $37.5 million. The updated revenue represents a YoY increase of approximately 19% compared with the revenue of $32.9 million in fiscal year 2014
This one is about to breakout. Once it breaks 30c it will fly
LPTN is about to breakout.
Company has 65c/share and only 13 million share float
Warrant conversion is over.
See ya at 45c in a few days
Best biotec stocks to own.....easy double
Read the stuff about Lpathomab. I am sure LPTN will find willing partners to share the clinical costs
and LPATH has 65c/share cash and no debt.....and a 13 million share float
LPTN has 65c/share cash and no debt.
Lpath, Inc.(LTPN) the industry leader in bioactive lipid-targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application (IND) for Lpathomab™. The FDA informed the company that the Phase 1 clinical trial to study Lpathomab may now be initiated. Lpath plans to begin this trial upon investigational review board approvals and anticipates the first subject to be dosed within two months.
Lpathomab is an antibody targeting lysophosphatidic acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies have shown strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy. Other preclinical studies have also demonstrated the potential for Lpathomab as a treatment for traumatic brain injury, and preclinical studies for this indication are currently underway in conjunction with the U.S. Department of Defense at Walter Reed Army Institute of Research as well as at academic institutions.
In addition to advancing Lpathomab into the clinic, Lpath intends to generate in vivo data in select programs, including Altepan™ and other earlier stage preclinical candidates, in order to identify the company's next clinical candidates and indications to pursue. Simultaneously, Lpath will actively explore partnering, licensing and monetization options for its pipeline assets. Lpath's proprietary discovery platform continues to be effective at creating bioactive lipid-targeted monoclonal antibody therapeutics.
Callate macumbero tonto